Cosmax (A192820) Q1 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2025 earnings summary
23 Jun, 2026Executive summary
Q1 2025 revenue rose 11.7% year-over-year to KRW 588.6 billion, driven by strong growth in Korea and Southeast Asia, while the US saw a decline.
Operating profit increased 13.0% year-over-year to KRW 51.3 billion, with a record high Q1 operating margin of 8.7%.
Net profit dropped 45.8% year-over-year to KRW 10.6 billion, impacted by non-operating losses and a significant one-off expense.
The company maintains its position as a global leader in cosmetics ODM, with over 90% of sales from ODM products and a diversified international client base.
Significant investments in R&D and sustainability, including EcoVadis Gold and CDP A- ratings, reinforce competitive advantages.
Financial highlights
Korea sales up 15.0% year-over-year to KRW 362.8 billion; operating profit up 14.0%.
China sales up 3.4% to KRW 162.7 billion; operating profit turned negative.
Indonesia sales up 22.8% to KRW 29.6 billion; Thailand sales up 152.1% to KRW 23.9 billion, both with improved profitability.
US sales down 26.0% to KRW 28.7 billion; net loss narrowed.
Gross profit increased 4.5% year-over-year to KRW 104.8 billion; SG&A costs decreased 3.0%.
Gross margin was 17.8%, slightly up from 17.5% in the prior year.
Basic EPS for Q1 2025 was KRW 717, compared to KRW 1,696 in Q1 2024.
Outlook and guidance
US region expects improved performance in the second half as new client sales ramp up.
Continued investment in production capacity in Korea to meet high demand.
The company aims to maintain growth by expanding global production capacity and strengthening R&D.
Focus remains on adapting to regulatory changes and evolving consumer trends in major markets.
Latest events from Cosmax
- H1 2024 revenue reached ₩1,078.3B with net income of ₩54.9B, led by Korea and Southeast Asia growth.A192820
Q2 202423 Jun 2026 - H1 2025 revenue hit KRW 1,212.1B, with net profit impacted by non-operating expenses.A192820
Q2 202523 Jun 2026 - Revenue up 1.0% YoY, but profit declined on one-off costs; R&D and ESG efforts remain strong.A192820
Q3 202523 Jun 2026 - Q1 2026 revenue up 15.9% YoY and net profit up 312.1%, driven by Korea and China growth.A192820
Q1 202631 May 2026 - Strong revenue and profit growth in 4Q 2025, led by health supplement and holding segments.A192820
Q4 20258 Mar 2026 - Korea and Southeast Asia drove robust profit growth, offsetting China and US weakness.A192820
Q3 202420 Feb 2026 - Record Q4 profit growth driven by Korea and Southeast Asia, with net profit turning positive.A192820
Q4 202420 Feb 2026